J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'

Putting a damper on a years-long kinship, J&J says it’s partly backing out of two license agreements for Alkermes’ nanoparticle technology, which the pharma giant claims it doesn’t use.

There’s only one problem: Alkermes doesn’t agree, and CEO Richard Pops says he’ll “explore all options” at the company’s disposal to prevent J&J from infringing on what he says are Alkermes’ contractual rights.